Eribulin Mesylate Injection
Product Images NDC 40033-364

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 40033-364). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kindos Pharmaceuticals Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Package (Eribulin Mesylate Injection 1 mg/2 mL Carton)

Carton packaging label for ERIBULIN MESYLATE Injection 1 mg/2 mL (0.5 mg/mL) sterile solution for intravenous use. The label notes it is a cytotoxic agent supplied in single-dose vials with unused portion discard instructions. Distributed by Xiling Lab, made in China. Includes storage instructions and barcode.*

FDA Label Image

Figure 1 (Eribulin K32 Figure1 V2)

A survival curve chart comparing the proportion of patients alive over time (in months) between eribulin mesylate injection (N=508) and a control group (N=254). The chart shows higher survival proportions for the eribulin mesylate group across the 36-month period, with corresponding numbers of patients at risk provided below the x-axis.*

FDA Label Image

Figure 2 (Eribulin K32 Figure2 V2)

A survival probability Kaplan-Meier curve comparing eribulin mesylate injection with dacarbazine over survival time in months. The chart plots survival probability on the vertical axis against time on the horizontal axis, showing survival differences between eribulin mesylate and dacarbazine groups with a table of subjects at risk below the graph for each treatment over time.*

FDA Label Image

Structural Formula (Eribulin K32 Structure V2)

Chemical structure diagram of eribulin mesylate, the active ingredient in ERIBULIN MESYLATE injection 0.5 mg/mL by Kindos Pharmaceuticals Co., Ltd. The structure includes multiple cyclic components, hydroxyl, amine, and methylsulfonic acid groups.*

FDA Label Image

Principal Display Package (Eribulin Mesylate Injection 1 mg/2 mL Vial Label)

Eribulin Mesylate Injection 1 mg/2 ml (0.5 mg/ml) sterile solution label. The label indicates it is for intravenous use and is a cytotoxic agent. Storage instructions specify 25°C with permitted excursions from 15° to 30°C. Distributed by Xiling Lab Co., Ltd. in Chengdu, Sichuan, China. The label includes prescription use designation and dosing instructions to see accompanying information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.